SODIUM-GLUCOSE COTRANSPORTER2 INHIBITORS IN HEART FAILURE

被引:0
作者
Kazmierski, Wojciech [1 ]
Jurek, Jakub [1 ]
Lis, Paulina [2 ]
Lis, Anna [2 ]
Ziobro, Anna [4 ]
Ziomek, Mateusz [3 ]
Camlet, Katarzyna [4 ]
Kocur, Kinga [5 ]
机构
[1] Andrzej Frycz Modrzewski Krakow Univ, Fac Med & Hlth Sci, Krakow, Poland
[2] Med Univ Silesia, Leszek Giec Upper Silesian Med Ctr, PL-40635 Katowice, Poland
[3] Mil Inst Med, Natl Res Inst, PL-04141 Warsaw, Poland
[4] Dist Hosp Zakopane, PL-34500 Zakopane, Poland
[5] Dist Hosp Oswiecim, PL-32600 Oswiecim, Poland
来源
PROSPECTS IN PHARMACEUTICAL SCIENCES | 2024年 / 22卷 / 03期
关键词
Inhibitors SGLT2; Heart failure; Cardiology; REDUCED EJECTION FRACTION; ESC GUIDELINES; CARDIOVASCULAR OUTCOMES; SGLT2; INHIBITORS; EUROPEAN-SOCIETY; EMPAGLIFLOZIN; INFLAMMATION; ASSOCIATION; MECHANISMS; MORTALITY;
D O I
10.56782/pps.240
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Heart failure (HF) is a serious problem in a modern world, with increasing prevalence among ageing populations. The use of sodium-glucose cotransporter2 (SGLT2) inhibitors, originally intended to treat type 2 diabetes, has revolutionised the treatment of HF. In this review article, we present the latest evidence on the mechanism of action of SGLT2 inhibitors, also called flosins, in HF. The primary mechanism of action of flosins is to reduce glucose reabsorption from glomerular filtration in the proximal renal tubule with a concomitant reduction in sodium reabsorption, leading to urinary glucose excretion and osmotic diuresis. Based on experimental findings, several pleiotropic effects of SGLT2 inhibitors have been proposed. Mechanisms also include regulation of inflammatory and oxidative pathways along with improved endothelial function. Recent multicentre studies of SGLT2 inhibitors have shown that they reduce hospitalisations for heart failure after their use, regardless of type 2 diabetes and the degree of cardiac systolic dysfunction.
引用
收藏
页码:225 / 232
页数:8
相关论文
共 52 条
  • [1] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao P.
    Bocchi, Edimar
    Boehm, Michael
    Brunner-La Rocca, Hans-Peter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure-Valenzuela, Eduardo
    Giannetti, Nadia
    Gomez-Mesa, Juan Esteban
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Carson, Peter
    Lam, Carolyn Su Ping
    Marx, Nikolaus
    Zeller, Cordula
    Sattar, Naveed
    Jamal, Waheed
    Schnaidt, Sven
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) : 1451 - 1461
  • [2] Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
    Aroor, Annayya R.
    Das, Nitin A.
    Carpenter, Andrea J.
    Habibi, Javad
    Jia, Guanghong
    Ramirez-Perez, Francisco I.
    Martinez-Lemus, Luis
    Manrique-Acevedo, Camila M.
    Hayden, Melvin R.
    Duta, Cornel
    Nistala, Ravi
    Mayoux, Eric
    Padilla, Jaume
    Chandrasekar, Bysani
    DeMarco, Vincent G.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [3] Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure
    Bedi, Kenneth C., Jr.
    Snyder, Nathaniel W.
    Brandimarto, Jeffrey
    Aziz, Moez
    Mesaros, Clementina
    Worth, Andrew J.
    Wang, Linda L.
    Javaheri, Ali
    Blair, Ian A.
    Margulies, Kenneth B.
    Rame, J. Eduardo
    [J]. CIRCULATION, 2016, 133 (08) : 706 - 716
  • [4] Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
    Benham, Jamie L.
    Booth, Jane E.
    Sigal, Ronald J.
    Daskalopoulou, Stella S.
    Leung, Alexander A.
    Rabi, Doreen M.
    [J]. IJC HEART & VASCULATURE, 2021, 33
  • [5] Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure - The Rotterdam Study
    Bleumink, GS
    Knetsch, AM
    Sturkenboom, MCJM
    Straus, SMJM
    Hofman, A
    Deckers, JW
    Witteman, JCM
    Stricker, BHC
    [J]. EUROPEAN HEART JOURNAL, 2004, 25 (18) : 1614 - 1619
  • [6] Soluble Uric Acid Activates the NLRP3 Inflammasome
    Braga, Tarcio Teodoro
    Forni, Maria Fernanda
    Correa-Costa, Matheus
    Ramos, Rodrigo Nalio
    Barbuto, Jose Alexandre
    Branco, Paola
    Castoldi, Angela
    Hiyane, Meire Ioshie
    Davanso, Mariana Rodrigues
    Latz, Eicke
    Franklin, Bernardo S.
    Kowaltowski, Alicia J.
    Saraiva Camara, Niels Olsen
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [7] A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress
    Bray, Jonathan J. H.
    Foster-Davies, Harri
    Stephens, Jeffrey W.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 168
  • [8] Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
    Chilton, R.
    Tikkanen, I.
    Cannon, C. P.
    Crowe, S.
    Woerle, H. J.
    Broedl, U. C.
    Johansen, O. E.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (12) : 1180 - 1193
  • [9] 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
    Cosentino, Francesco
    Grant, Peter J.
    Aboyans, Victor
    Bailey, Clifford J.
    Ceriello, Antonio
    Delgado, Victoria
    Federici, Massimo
    Filippatos, Gerasimos
    Grobbee, Diederick E.
    Hansen, Tina Birgitte
    Huikuri, Heikki, V
    Johansson, Isabelle
    Juni, Peter
    Lettino, Maddalena
    Marx, Nikolaus
    Mellbin, Linda G.
    Ostgren, Carl J.
    Rocca, Bianca
    Roffi, Marco
    Sattar, Naveed
    Seferovic, Petar M.
    Sousa-Uva, Miguel
    Valensi, Paul
    Wheeler, David C.
    Piepoli, Massimo Francesco
    Birkeland, Kare, I
    Adamopoulos, Stamatis
    Ajjan, Ramzi
    Avogaro, Angelo
    Baigent, Colin
    Brodmann, Marianne
    Bueno, Hector
    Ceconi, Claudio
    Chioncel, Ovidiu
    Coats, Andrew
    Collet, Jean-Philippe
    Collins, Peter
    Cosyns, Bernard
    Di Mario, Carlo
    Fisher, Miles
    Fitzsimons, Donna
    Halvorsen, Sigrun
    Hansen, Dominique
    Hoes, Arno
    Holt, Richard I. G.
    Home, Philip
    Katus, Hugo A.
    Khunti, Kamlesh
    Komajda, Michel
    Lambrinou, Ekaterini
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 (02) : 255 - 323
  • [10] Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial
    Furtado, Remo H. M.
    Bonaca, Marc P.
    Raz, Itamar
    Zelniker, Thomas A.
    Mosenzon, Ofri
    Cahn, Avivit
    Kuder, Julia
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Ruff, Christian T.
    Nicolau, Jose C.
    Gause-Nilsson, Ingrid A. M.
    Fredriksson, Martin
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. CIRCULATION, 2019, 139 (22) : 2516 - 2527